MTT assay showed that CRISPR/Cas9-UCA1-(1+8) transfection impaired viability of 5637 and T24 bladder cancer cells, which became apparent after 48 h- transfection (Figure 3A). This evidence concerns the gene UCA1 and urinary bladder cancer.